SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing heightened trading volume and speculative momentum as community members discuss a potential breakout and its integration into the broader NFT and gaming ecosystem. While some traders are focused on short-term volatility and technical setups, others are debating its long-term utility and historical price performance.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors react to the company's strong Q1 earnings beat and optimistic guidance, which are being driven by a structural shift toward AI-fueled data center infrastructure. The stock has seen massive volume and price volatility as the market reprices the company's role in the optical interconnect supply chain, sparking intense debate among retail traders regarding whether the move is a sustainable re-rating or an overextended momentum squeeze.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively trade around significant volume and high short interest, with the community actively speculating that an imminent commercial deal or partnership news is on the horizon. Despite persistent skepticism regarding the lack of recurring revenue, sentiment is currently buoyed by hopeful 'dot-connecting' related to the firm's advanced semiconductor material integration and anticipated industry collaborations.

Harvest Portfolios Group Inc - Harvest Canadian High Income Shares ETF

Harvest Canadian High Income Shares ETF

Investors are closely monitoring the ETF following reports of dividend increases and shifts in underlying portfolio holdings. The community is actively debating the fund's role within broader income-focused portfolios and evaluating its performance relative to other yield-oriented strategies.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

VanEck Semiconductor ETF (SMH) is experiencing a parabolic, momentum-driven rally to all-time highs as traders pile into AI infrastructure, despite widespread community debate over whether this represents a sustainable megatrend or an overextended bubble. Investors are closely monitoring record-breaking winning streaks and extreme relative strength indicators, with discussions split between those riding the momentum and others hedging for an inevitable sector rotation or volatility reset.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors await a critical Phase 3 data readout for its hereditary angioedema therapy, with high short interest fueling anticipation for a potential short squeeze. The community is actively discussing the stock's significant price volatility and the potential impact of this binary event on the company's long-term position in the gene-editing sector.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is seeing renewed community interest as traders highlight its low circulating supply and potential for explosive price moves during DeFi market expansions. Supporters are actively discussing the token's governance role, its leverage-focused product suite, and the possibility of a breakout similar to previous cycles.

Chip

CHIP is seeing significant trading volume and social activity following its simultaneous listing on major platforms like Robinhood and Coinbase, fueling an intense community debate between those betting on its long-term AI infrastructure utility and those dismissing it as a short-lived pump-and-dump scheme. Investors are closely monitoring its price consolidation while debating whether the token's early volatility represents a genuine accumulation phase or a coordinated exit by insiders.

Toro Corp. is a shipping company, which engages in the acquisition, owning, chartering, and operation of oceangoing tanker vessels. The firm also provides seaborne transportation services for crude oil and refined petroleum products. It operates through the Aframax/LR2 Tanker and Handysize Tanker segments. The Aframax/LR2 Tanker segment includes vessels operated under time charter contracts, voyage charter contracts, and pools entered into by certain of the subsidiaries. The Handysize Tanker segment consists of vessels operated in a Handysize pool. The company was founded on July 29, 2022 and is headquartered in Limassol, Cyprus.

Toro Corp

Toro Company 

Toro Company is currently trending due to a significant special dividend announcement that has attracted investor interest, alongside community discussions regarding its low float and potential for upward momentum. Many are highlighting the CEO's active participation in open-market share purchases, which is fueling speculation among traders about a possible short-squeeze setup and strong price action.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the community debates its critical role as a semiconductor packaging 'pick-and-shovel' play in the AI supply chain. Investors are closely monitoring the stock's performance amid portfolio rebalancing during high-volatility weeks, weighing its potential for long-term growth against the broader market's rotation into AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zurcher Kantonalbank Zurich Cantonalbank Acquires 219,479 Shares of Royalty Pharma PLC $RPRX

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 222.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 318,293 shares of the biopharmaceutical comp...

Royalty Pharma PLC $RPRX Shares Purchased by Torray Investment Partners LLC

Torray Investment Partners LLC increased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 5.9% in the fourth quarter, according to the company in its most recent filing...

Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) has been assigned a consensus rating of "Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Six research...

Moran Wealth Management LLC Grows Position in Royalty Pharma PLC $RPRX

Moran Wealth Management LLC boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 20.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange...

KBC Group NV Trims Holdings in Royalty Pharma PLC $RPRX

KBC Group NV trimmed its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 13.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 163,561 shares of the biopharmaceutical...

Royalty Pharma PLC (NASDAQ:RPRX) Declares $0.24 Quarterly Dividend

Royalty Pharma PLC (NASDAQ:RPRX) declared a quarterly dividend on Friday, April 17th. Shareholders of record on Friday, May 15th will be given a dividend of 0.235 per share by the biopharmaceutical...

Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High  - Should You Buy?

Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week High - Time to Buy...

Sumitomo Mitsui Trust Group Inc. Acquires 166,403 Shares of Royalty Pharma PLC $RPRX

Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 15.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,268,044 shares of the biopharmaceutical company's stock aft...

Foster Victor Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX

Foster Victor Wealth Advisors LLC acquired a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund...

Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

RPRX
Royalty Pharma plc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RPRX News

RPRXRoyalty Pharma plc - Ordinary Shares - Class A